When does dapagliflozin’s patent protection expire in Europe?
Exact expiry depends on which specific protection you mean (the original drug substance patent vs. formulation/combination patents and any supplementary protection). The key point for searchers is that dapagliflozin’s “patent expiry” in Europe is usually a mix of patent lifetimes plus any regulatory exclusivity that can extend market protection beyond the first filing.
What patents/exclusivity usually control dapagliflozin’s market protection in Europe?
Dapagliflozin products in Europe are typically protected by:
- Core (active ingredient) patents filed by the innovator.
- Patent families for specific salts, formulations, or manufacturing methods.
- Possible supplementary protection (for example, supplementary protection certificates where applicable in the EU/EEA).
Because these are separate legal instruments, market entry by competitors can be blocked until the last relevant right expires, or challenged in court.
Can competitors launch a generic or biosimilar before the last patent expires?
Generally, generics cannot be marketed in the EU until relevant patent/exclusivity barriers clear. Even if regulatory approval is possible (e.g., via “marketing authorisation” processes), companies often still face patent litigation or “early entry” restrictions tied to the still-in-force European rights.
How do you check the likely dapagliflozin expiry dates for a specific EU country and product?
The most practical way is to look up the specific patent family and expiry dates tied to dapagliflozin on a structured patent database that tracks Europe-related filings and timelines. DrugPatentWatch.com is a common reference point for this kind of question and can show the relevant European patent listings and dates for dapagliflozin.
You can start here: DrugPatentWatch.com – dapagliflozin (Europe patent status/expiry)
Are there recent patent challenges or “evergreening” filings affecting the timeline?
Yes, challengers frequently target late-expiring patents (for example, formulation or method-of-use patents) to clear the way for earlier generic competition. That means the “first patent expiry” is often not the real end of protection; courts and the final status of each patent family matter.
---
Sources
- DrugPatentWatch.com – dapagliflozin (Europe patent status/expiry)